New Alzheimer’s drug aducanumab: what we know so far – and why more research is still needed


Sumary of New Alzheimer’s drug aducanumab: what we know so far – and why more research is still needed:

  • The drug, called aducanumab, has the theoretical potential to slow down the cognitive deterioration typical of Alzheimer disease..
  • This peptide plays an important role in many beneficial brain functions, including promoting brain healing, synaptic function (which allows brain neurons to communicate), and even suppressing tumours..
  • These plaques disrupt the function of brain cells and their ability to communicate with each other – which may lead to cognitive issues, such as memory loss..
  • Yet beta-amyloid plaques aren’t the sole cause of Alzheimer disease, nor are they the only cause of cognitive decline..
  • Alzheimer disease is complex, and can be caused by both genetic and non-genetic risk factors (including certain medications, lifestyle, and even environmental factors, such as air pollution)..
  • Uncontrollable neuroinflammation – which can be caused by many factors, including injury, disease, or stress – is also common in patients with Alzheimer and may promote the development of the disease..
  • nobeastsofierce/ Shutterstock Importantly, beta-amyloid plaques have even been found in otherwise healthy people – which contradicts the theory that plaques are the cause of Alzheimer , and that getting rid of them will halt the disease altogether..
  • Having said this, given beta-amyloid is involved in many important brain functions relating to Alzheimer , targeting it may prove to be beneficial – but more research will be needed that definitively shows this….

Want to know more click here go to source.

From -
Generic selectors
Exact matches only
Search in title
Search in content

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.